東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Linked to FindBook

Google Book

Amazon

博客來

Ion channels as targets in drug discovery

Record Type:	Electronic resources : Monograph/item
Title/Author:	Ion channels as targets in drug discovery/ edited by Gary Stephens, Edward Stevens.
other author:	Stephens, Gary.
Published:	Cham :Springer International Publishing : : 2024.,
Description:	ix, 537 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	Ion Channels as Targets in Drug Discovery: outlook and perspectives -- Conservation of ligand binding between voltage-gated sodium and T-type calcium channels -- The presynaptic α2δ protein family and their therapeutic potential -- Sodium channel in central hyperexcitability disease -- Therapeutic targeting of voltage-gated potassium channels -- The contribution of genetic sequencing information to the identification and functional characterisation of two pore domain (K2P) channels as viable therapeutic targets -- The voltage-gated potassium channel KV2.1 as a multicellular drug target -- Cystic fibrosis transmembrane conductance regulator (CFTR)-targeted therapeutics for cystic fibrosis -- Validation of TMEM16A modulation as a therapeutic approach for the treatment of cystic fibrosis - the discovery of novel TMEM16A potentiators -- Targeting acid-sensing ion channels in disease -- Transient Receptor Potential Canonical (TRPC) as a Therapeutic Drug Target -- Nicotinic receptors of the neuronal and non-neuronal cholinergic systems as therapeutic targets: Opportunities and limitations -- Purinergic P2X receptors as therapeutic targets -- Immune Cell Ion Channels as Therapeutic Targets -- Ion channel tools and therapeutics from venoms and toxins.
Contained By:	Springer Nature eBook
Subject:	Ion channels. -
Online resource:	https://doi.org/10.1007/978-3-031-52197-3
ISBN:	9783031521973

Ion channels as targets in drug discovery
Ion channels as targets in drug discovery[electronic resource] /edited by Gary Stephens, Edward Stevens. - Cham :Springer International Publishing :2024. - ix, 537 p. :ill. (some col.), digital ;24 cm.

Ion Channels as Targets in Drug Discovery: outlook and perspectives -- Conservation of ligand binding between voltage-gated sodium and T-type calcium channels -- The presynaptic α2δ protein family and their therapeutic potential -- Sodium channel in central hyperexcitability disease -- Therapeutic targeting of voltage-gated potassium channels -- The contribution of genetic sequencing information to the identification and functional characterisation of two pore domain (K2P) channels as viable therapeutic targets -- The voltage-gated potassium channel KV2.1 as a multicellular drug target -- Cystic fibrosis transmembrane conductance regulator (CFTR)-targeted therapeutics for cystic fibrosis -- Validation of TMEM16A modulation as a therapeutic approach for the treatment of cystic fibrosis - the discovery of novel TMEM16A potentiators -- Targeting acid-sensing ion channels in disease -- Transient Receptor Potential Canonical (TRPC) as a Therapeutic Drug Target -- Nicotinic receptors of the neuronal and non-neuronal cholinergic systems as therapeutic targets: Opportunities and limitations -- Purinergic P2X receptors as therapeutic targets -- Immune Cell Ion Channels as Therapeutic Targets -- Ion channel tools and therapeutics from venoms and toxins.

This book is built around ion channel research and, more specifically, ion channels as important therapeutic drug targets. Under the editorial leadership of Gary Stephens in academic research and Edward Stevens from industry, the aim is to bring these strands together to provide a cutting-edge translational reference on ion channel drug discovery. Exploiting our knowledge of ion channel structure and function has clear current and future potential to intervene and correct the pathophysiology associated with debilitating conditions, including cardiovascular disease, diabetes, cystic fibrosis, pain, epilepsy, and neurodegenerative disorders. Individual chapters have a disease focus, also providing a "case study story" that will also appeal to a clinical audience, while background information on a given ion channel is presented to provide a solid reference for undergraduate and postgraduate teaching.

ISBN: 9783031521973

Standard No.: 10.1007/978-3-031-52197-3doiSubjects--Topical Terms:

656244
Ion channels.

LC Class. No.: QH603.I54

Dewey Class. No.: 571.64

Ion channels as targets in drug discovery
LDR:03173nmm a22003255a 4500 001 2369527
003 DE-He213
005 20240425093343.0
006 m d
007 cr nn 008maaau
008 241127s2024 sz s 0 eng d
020 $a 9783031521973 $q (electronic bk.)
020 $a 9783031521966 $q (paper)
024 7 $a 10.1007/978-3-031-52197-3 $2 doi
035 $a 978-3-031-52197-3
040 $a GP $c GP
041 0 $a eng
050 4 $a QH603.I54
072 7 $a PSAN $2 bicssc
072 7 $a SCI089000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 571.64 $2 23
090 $a QH603.I54 $b I64 2024
245 1 0 $a Ion channels as targets in drug discovery $h [electronic resource] / $c edited by Gary Stephens, Edward Stevens.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2024.
300 $a ix, 537 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Ion Channels as Targets in Drug Discovery: outlook and perspectives -- Conservation of ligand binding between voltage-gated sodium and T-type calcium channels -- The presynaptic α2δ protein family and their therapeutic potential -- Sodium channel in central hyperexcitability disease -- Therapeutic targeting of voltage-gated potassium channels -- The contribution of genetic sequencing information to the identification and functional characterisation of two pore domain (K2P) channels as viable therapeutic targets -- The voltage-gated potassium channel KV2.1 as a multicellular drug target -- Cystic fibrosis transmembrane conductance regulator (CFTR)-targeted therapeutics for cystic fibrosis -- Validation of TMEM16A modulation as a therapeutic approach for the treatment of cystic fibrosis - the discovery of novel TMEM16A potentiators -- Targeting acid-sensing ion channels in disease -- Transient Receptor Potential Canonical (TRPC) as a Therapeutic Drug Target -- Nicotinic receptors of the neuronal and non-neuronal cholinergic systems as therapeutic targets: Opportunities and limitations -- Purinergic P2X receptors as therapeutic targets -- Immune Cell Ion Channels as Therapeutic Targets -- Ion channel tools and therapeutics from venoms and toxins.
520 $a This book is built around ion channel research and, more specifically, ion channels as important therapeutic drug targets. Under the editorial leadership of Gary Stephens in academic research and Edward Stevens from industry, the aim is to bring these strands together to provide a cutting-edge translational reference on ion channel drug discovery. Exploiting our knowledge of ion channel structure and function has clear current and future potential to intervene and correct the pathophysiology associated with debilitating conditions, including cardiovascular disease, diabetes, cystic fibrosis, pain, epilepsy, and neurodegenerative disorders. Individual chapters have a disease focus, also providing a "case study story" that will also appeal to a clinical audience, while background information on a given ion channel is presented to provide a solid reference for undergraduate and postgraduate teaching.
650 0 $a Ion channels. $3 656244
650 0 $a Ion channels $x Effect of drugs on. $3 3710534
650 0 $a Drug development. $3 716904
650 1 4 $a Neuroscience. $3 917253
650 2 4 $a Neurochemistry. $3 657592
650 2 4 $a Pharmacology. $3 634543
700 1 $a Stephens, Gary. $3 3714249
700 1 $a Stevens, Edward. $3 3714250
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-52197-3
950 $a Biomedical and Life Sciences (SpringerNature-11642)